CLARIFICATION
An article in the August, 2017 issue of The Chronicle of Skin & Allergy (New therapies offer options for patients with IH, page 11) incorrectly described two elements of oral propranolol 3.75 mgmL (Hemangiol, Pierre Fabre Dermo-Cosmetique Canada Inc.).
The article should have noted that the branded product Hemangiol became available in the Canadian marketplace in the second quarter of 2017.
Additionally, the syringe provided with Hemangiol is calibrated in millilitres, not milligrams as indicated in the report.